Literaturverzeichnis

1. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC: Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 61: 827-837, 1967

2. Sollinger HW, Odorico JS, Knechtle SJ, D'Alessandro AM, Kalayoglu M, Pirsch JD: Experience with 500 simultaneous pancreas-kidney transplants. Ann.Surg. 228: 284-296, 1998

3. Cook K, Sollinger HW, Warner T, Kamps D, Belzer FO: Pancreaticocystostomy: an alternative method for exocrine drainage of segmental pancreatic allografts. Transplantation 35: 634-636, 1983

4. Philosophe B, Farney AC, Schweitzer EJ, Colonna JO, Jarrell BE, Krishnamurthi V, Wiland AM, Bartlett ST: Superiority of portal venous drainage over systemic venous drainage in pancreas transplantation: a retrospective study. Ann.Surg. 234: 689-696, 2001

5. Odorico JS, Pirsch JD, Knechtle SJ, D'Alessandro AM, Sollinger HW: A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 66: 1751-1759, 1998

6. Gruessner RW, Burke GW, Stratta R, Sollinger H, Benedetti E, Marsh C, Stock P, Boudreaux JP, Martin M, Drangstveit MB, Sutherland DE, Gruessner A: A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 61: 261-273, 1996

7. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS: Sirolimus-tacrolimus combination immunosuppression. Lancet 355: 376-377, 2000

8. Anonymous: Annual Report of the International Pancreas Transpalantation Registry. IPTR Newsletter 14: 1-28, 2002

9. Becker BN, Brazy PC, Becker YT, Odorico JS, Pintar TJ, Collins BH, Pirsch JD, Leverson GE, Heisey DM, Sollinger HW: Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int. 57: 2129-2135, 2000

10. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman A, Magee JC, Cibrik D, Wolfe RA, Port FK, Agodoa L, Kaufman DB, Kaplan B: The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 71: 82-90, 2001

11. Smets YF, Westendorp RG, van der Pijl JW, de Charro FT, Ringers J, de Fijter JW, Lemkes HH: Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet 353: 1915-1919, 1999

12. Sinclair NR: Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ. 147: 645-657, 1992

13. Opelz G: Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 58: 443-446, 1994

14. Hricik DE, O'Toole MA, Schulak JA, Herson J: Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J.Am.Soc.Nephrol. 4: 1300-1305, 1993

15. Sandrini S, Maiorca R, Scolari F, Cancarini G, Setti G, Gaggia P, Cristinelli L, Zubani R, Bonardelli S, Maffeis R, Portolani N, Nodari F, Giulini SM: A prospective randomized trial on azathioprine addition to cyclosporine versus cyclosporine monotherapy at steroid withdrawal, 6 months after renal transplantation. Transplantation 69: 1861-1867, 2000

16. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J.Am.Soc.Nephrol. 11: 1910-1917, 2000

17. Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ: Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 348: 643-648, 1996

18. Cantarovich D, Palneau J, Couderc JP, Murat A, Hourmant M, Boatard R, Dantal J, Karam G, Bouchot O, Soulillou JP: Maintenance immunosuppression without corticosteroids following combined pancreas and kidney transplantation. Transplant.Proc. 23: 2224-2225, 1991

19. Hricik DE, Bartucci MR, Mayes JT, Schulak JA: The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 54: 868-871, 1992

20. Gruessner RW, Sutherland DE, Parr E, Humar A, Gruessner AC: A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transplant.Proc. 33: 1663-1664, 2001

21. Humar A, Parr E, Drangstveit MB, Kandaswamy R, Gruessner AC, Sutherland DE: Steroid withdrawal in pancreas transplant recipients. Clin.Transplant. 14: 75-78, 2000

22. Jordan ML, Chakrabarti P, Luke P, Shapiro R, Vivas CA, Scantlebury VP, Fung JJ, Starzl TE, Corry RJ: Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation 69: 265-271, 2000

23. Kaufman DB, Leventhal JR, Koffron AJ, Gallon LG, Parker MA, Fryer JP, Abecassis MM, Stuart FP: A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 73: 169-177, 2002

24. Cantarovich D, Giral-Classe M, Hourmant M, Dantal J, Blancho G, Karam G, Soulillou JP: Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation 69: 1505-1508, 2000

24a. Birkeland SA: Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 71: 1089-1090, 2001

25. Dubus I, Vendrely B, Christophe I, Labouyrie JP, Delmas Y, Bonnet J, Combe C: Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int. 62: 857-867, 2002

26. Brunner E, Langer F.: Nicht parametrische Analyse longitudinaler Daten. München-Wien, Oldenbourg Verlag, 1999

27. Anonymous: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Guidline 4: Estimation of GFR. Am.J.Kidney Dis. 39: S76-92, 2002

28. Becker BN, Odorico JS, Becker YT, Groshek M, Werwinski C, Pirsch JD, Sollinger HW: Simultaneous pancreas-kidney and pancreas transplantation. J.Am.Soc.Nephrol. 12: 2517-2527, 2001

29. Tesi RJ, Henry ML, Elkhammas EA, Davies EA, Ferguson RM: The frequency of rejection episodes after combined kidney-pancreas transplant--the impact on graft survival. Transplantation 58: 424-430, 1994

30. Kahl A, Lorenz F, Pohle K, Bechstein W, Platz K, Neuhaus P, Frei U: Prednisolone withdrawal after pancreas-kidney transplantation in patients treated with Tacrolimus and Mycophenolate Mofetil. Transplantation 67: S223, 1999

31. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE: Incidence and long-term cost of steroid-related side effects after renal transplantation. Am.J.Kidney Dis. 33: 829-839, 1999

32. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, Morris RE: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59: 655-661, 1995

33. Morris RE: Vascular and cellular mechanisms of chronic renal allograft dysfunction. Transplantation 71: SS37-SS41, 2001

34. Jolicoeur EM, Qi S, Xu D, Dumont L, Daloze P, Chen H: Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 75: 54-59, 2003

35. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M: Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356: 645-649, 2000

36. Danpanich E, Kasiske BL: Risk factors for cancer in renal transplant recipients. Transplantation 68: 1859-1864, 1999

37. Soulillou JP, Giral M: Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 72: S89-S93, 2001

38. Penn I: Cancers complicating organ transplantation. N.Engl.J.Med. 323: 1767-1769, 1990

39. Tremblay F, Fernandes M, Habbab F, deB E, Loertscher R, Meterissian S: Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann.Surg.Oncol. 9: 785-788, 2002

40. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat.Med. 8: 128-135, 2002

41. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M: Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73: 1565-1572, 2002

42. Kahl A, Bechstein WO, Lorenz F, Steinberg J, Pohle C, Kampf D, Muller A, Settmacher U, Neuhaus P, Frei U: Long-term prednisolone withdrawal after pancreas and kidney transplantation in patients treated with ATG, tacrolimus, and mycophenolate mofetil. Transplant.Proc. 33: 1694-1695, 2001

43. Ahsan N, Hricik D, Matas A, Rose S, Tomlanovich S, Wilkinson A, Ewell M, McIntosh M, Stablein D, Hodge E: Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 68: 1865-1874, 1999

44. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H: Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 70: 1352-1359, 2000

45. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, Hilbrands LB, van Gelder T: Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J.Am.Soc.Nephrol. 13: 1365-1373, 2002

46. Berki T, Tavakoli A, Nagy KK, Nagy G, Nemeth P: Alterations of glucocorticoid receptor expression during glucocorticoid hormone therapy in renal transplant patients. Transpl.Int. 15: 132-138, 2002

47. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, Trpkov K, Solez K, Jeffery J: Beneficial effects of treatment of early subclinical rejection: a randomized study. J.Am.Soc.Nephrol. 9: 2129-2134, 1998

48. Ishikawa A, Flechner SM, Goldfarb DA, Myles JL, Modlin CS, Boparai N, Papajcik D, Mastroianni B, Novick AC: Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome. Transplantation 68: 1318-1324, 1999

49. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63: 977-983, 1997

50. Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Gores PF, Gruessner RW, Najarian JS: Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 55: 993-995, 1993

51. Sutherland DE, Gruessner RW, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS: Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann.Surg. 233: 463-501, 2001

52. Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 66: 1736-1740, 1998

53. Shishido S, Asanuma H, Nakai H, Mori Y, Satoh H, Kamimaki I, Hataya H, Ikeda M, Honda M, Hasegawa A: The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J.Am.Soc.Nephrol. 14: 1046-1052, 2003

54. Hricik DE, Phinney MS, Weigel KA, Knauss TC, Schulak JA: Long-term renal function in type I diabetics after kidney or kidney-pancreas transplantation: influence of number, timing, and treatment of acute rejection episodes. Transplantation 64: 1283-1288, 1997

55. Leggat JE, Jr., Ojo AO, Leichtman AB, Port FK, Wolfe RA, Turenne MN, Held PJ: Long-term renal allograft survival: prognostic implication of the timing of acute rejection episodes. Transplantation 63: 1268-1272, 1997

56. Stratta RJ: Late acute rejection episodes after vascularized pancreas transplantation. Transplant.Proc. 30: 1560-1561, 1998

57. Walker JA, Klassen DK, Hooper FJ, Hoehn-Saric EW, Schweitzer EJ, Johnson LB, Bartlett ST, Weir MR: Late pancreas allograft rejection. Preliminary experience with factors predisposing to rejection. Transplantation 62: 539-543, 1996

58. Sivaraman P, Nussbaumer G, Landsberg D: Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am.J.Kidney Dis. 37: 1162-1169, 2001

59. Ericzon BG, Wijnen RM, Kubota K, Kootstra G, Groth CG: FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. Transplantation 54: 615-620, 1992

60. Anonymous. Third Report of the National Cholesterol Education Program: Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH. Publication No 01-3670, 1-27. 2001. NIH. Ref Type: Report

61. La Rocca E, Secchi A, Parlavecchia M, Bonfatti D, Ragogna F, Di C, V, Pozza G, Ruotolo G: Lipoprotein profile after combined kidney-pancreas transplantation in insulin dependent diabetes mellitus. Transpl.Int. 8: 190-195, 1995

62. Katz HH, Nguyen TT, Velosa JA, Robertson RP, Rizza RA: Effects of systemic delivery of insulin on plasma lipids and lipoprotein concentrations in pancreas transplant recipients. Mayo Clin.Proc. 69: 231-236, 1994

63. Luzi L, Groop LC, Perseghin G, Taskinen MR, Hilden H, Bianchi E, Terruzzi I, Dodesini AR, Di C, V, Pozza G: Effect of pancreas transplantation on free fatty acid metabolism in uremic IDDM patients. Diabetes 45: 354-360, 1996

64. Foger B, Konigsrainer A, Ritsch A, Lechleitner M, Steurer W, Margreiter R, Patsch JR: Pancreas transplantation modulates reverse cholesterol transport. Transpl.Int. 12: 360-364, 1999

65. Waltzer WC, Turner S, Frohnert P, Rapaport FT: Etiology and pathogenesis of hypertension following renal transplantation. Nephron 42: 102-109, 1986

66. Hricik DE, Chareandee C, Knauss TC, Schulak JA: Hypertension after pancreas-kidney transplantation: role of bladder versus enteric pancreatic drainage. Transplantation 70: 494-496, 2000

67. Ponticelli C, Montagnino G, Aroldi A, Angelini C, Braga M, Tarantino A: Hypertension after renal transplantation. Am.J.Kidney Dis. 21: 73-78, 1993

68. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G: Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 73: 732-736, 2002

69. Hollander AA, Hene RJ, Hermans J, van Es LA, van der Woude FJ: Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J.Am.Soc.Nephrol. 8: 294-301, 1997

70. Raja RM, Lerner L, Morris M: Hypertension with combined pancreas-kidney transplantation in patients with diabetic nephropathy. Transplantation 55: 1187-1188, 1993

71. La Rocca E, Gobbi C, Ciurlino D, Di C, V, Pozza G, Secchi A: Improvement of glucose/insulin metabolism reduces hypertension in insulin-dependent diabetes mellitus recipients of kidney-pancreas transplantation. Transplantation 65: 390-393, 1998

72. Lorenz F, Kahl A, Pohle C, Kampf D, Bechstein W, Mueller A, Neuhaus P, Frei U: Bladder drained pancreas improves arterial hypertension in patients with simultaneous pancreas and kidney transplantation (SPK) [Abstract]. Transplantation 67: S173, 1999

73. Elliott MD, Kapoor A, Parker MA, Kaufman DB, Bonow RO, Gheorghiade M: Improvement in hypertension in patients with diabetes mellitus after kidney/pancreas transplantation. Circulation 104: 563-569, 2001

74. Margreiter R: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 359: 741-746, 2002

75. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 73: 775-782, 2002

76. Bruce DS, Woodle ES, Newell KA, Millis JM, Cronin DC, Loss GE, Grewal HP, Siegel CT, Pellar S, Josephson MA, Thistlethwaite JR, Jr.: Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant.Proc. 30: 1538-1540, 1998

77. Schulz T, Martin D, Heimes M, Klempnauer J, Buesing M: Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. Transplant.Proc. 30: 1533-1535, 1998

78. Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I: Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation 64: 1695-1700, 1997

79. Drachenberg CB, Papadimitriou JC, Farney A, Wiland A, Blahut S, Fink JC, Philosophe B, Schweitzer E, Lal T, Anderson L, Bartlett ST: Pancreas transplantation: the histologic morphology of graft loss and clinical correlations. Transplantation 71: 1784-1791, 2001

80. Gruessner RW, Sutherland DE, Troppmann C, Benedetti E, Hakim N, Dunn DL, Gruessner AC: The surgical risk of pancreas transplantation in the cyclosporine era: an overview. J.Am.Coll.Surg. 185: 128-144, 1997

81. Hopt UT, Benz S, Pfeffer F, Schareck W, Irkin I, Busing M: Simultaneous pancreas/kidney transplantation--the optimal therapy for type I diabetics with end-stage renal disease in Europe, too? Transpl.Int. 7 Suppl 1: S414-S416, 1994

82. Kandaswamy R, Humar A, Gruessner AC, Harmon JV, Granger DK, Lynch S, Sutherland DE, Gruessner RW: Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras. Transplant.Proc. 31: 602-603, 1999

83. Kessler L, Wiesel ML, Boudjema K, Lutun E, Moulin B, Cazenave JP, Wolf P, Pinget M: Possible involvement of Von Willebrand factor in pancreatic graft thrombosis after kidney-pancreas transplantation: a retrospective study. Clin.Transplant. 12: 35-42, 1998

84. Malyszko J, Malyszko JS, Takada A, Mysliwiec M: Effects of immunosuppressive drugs on platelet aggregation in vitro. Ann.Transplant. 7: 55-68, 2002

85. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M: The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Transplantation 62: 828-830, 1996

86. Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Pawlak K, Mysliwiec M: A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrol.Dial.Transplant. 16: 1692-1696, 2001

87. Caldara R, La Rocca E, Maffi P, Secchi A: Effects of pancreas transplantation on late complications of diabetes and metabolic effects of pancreas and islet transplantation. J.Pediatr.Endocrinol.MeTab.12 Suppl 3: 777-787, 1999

88. Nankivell BJ, Chapman JR, Bovington KJ, Spicer ST, O'Connell PJ, Allen RD: Clinical determinants of glucose homeostasis after pancreas transplantation. Transplantation 61: 1705-1711, 1996

89. Jindal RM, Sidner RA, Milgrom ML: Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 16: 242-257, 1997

90. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, Papadimitriou JC: Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 68: 396-402, 1999

91. Berweck S, Kahl A, Bechstein W, Platz K, Muller U, Neuhaus P, Frei U: Clinical use of the euglycemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation. Transplant.Proc. 30: 1944-1945, 1998

92. Gaber AO, Shokouh-Amiri MH, Hathaway DK, Hammontree L, Kitabchi AE, Gaber LW, Saad MF, Britt LG: Results of pancreas transplantation with portal venous and enteric drainage. Ann.Surg. 221: 613-622, 1995

93. Martin X, Petruzzo P, Dawahra M, Feitosa Tajra LC, Da Silva M, Pibiri L, Chapuis F, Dubernard JM, Lefrancois N: Effects of portal versus systemic venous drainage in kidney-pancreas recipients. Transpl.Int. 13: 64-68, 2000

94. Philosophe B: Portal versus systemic delivery of insulin: Immunologic benefits for pancreas transplantation. Curr Opin Organ Transplant 7: 180-184, 2002

95. Nymann T, Hathaway DK, Shokouh-Amiri MH, Gaber LW, Abu-el-Ella K, Abdulkarim AB, Gaber AO: Patterns of acute rejection in portal-enteric versus systemic-bladder pancreas-kidney transplantation. Clin.Transplant 12: 175-183, 1998

96. Cattral MS, Bigam DL, Hemming AW, Carpentier A, Greig PD, Wright E, Cole E, Donat D, Lewis GF: Portal venous and enteric exocrine drainage versus systemic venous and bladder exocrine drainage of pancreas grafts: clinical outcome of40 consecutive transplant recipients. Ann.Surg. 232: 688-695, 2000

97. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N.Engl.J.Med. 334: 952-957, 1996

98. Elliott TG, Viberti G: Relationship between insulin resistance and coronary heart disease in diabetes mellitus and the general population: a critical appraisal. Baillieres Clin.Endocrinol.MeTab. 7: 1079-1103, 1993

99. Stout RW: Hyperinsulinemia and atherosclerosis. Diabetes 45 Suppl 3: S45-S46, 1996

100. Anonymous: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853, 1998

101. Pou L, Brunet M, Cantarell C, Vidal E, Oppenheimer F, Monforte V, Vilardell J, Roman A, Martorell J, Capdevila L: Mycophenolic acid plasma concentrations: influence of comedication. Ther.Drug Monit. 23: 35-38, 2001

102. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther.Drug Monit. 23: 119-128, 2001

103. Gregoor PJ, de Sevaux RG, Hene RJ, Hesse CJ, Hilbrands LB, Vos P, van Gelder T, Hoitsma AJ, Weimar W: Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 68: 1603-1606, 1999

104. Cattaneo D, Gaspari F, Ferrari S, Stucchi N, Del Priore L, Perico N, Gotti E, Remuzzi G: Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin.Transplant 15: 402-409, 2001

105. Yamani MH, Starling RC, Goormastic M, Van Lente F, Smedira N, McCarthy P, Young JB: The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 69: 2326-2330, 2000

106. Hubner GI, Eismann R, Sziegoleit W: Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittelforschung. 50: 936-940, 2000

107. Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mast BJ, Hesse CJ, IJzermans JN, Weimar W: Mycophenolic acid trough levels after kidney transplantation in a cyclosporine-free protocol. Transpl.Int. 13 Suppl 1: S333-S335, 2000

108. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM: Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 65: 1127-1129, 1998

109. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G: Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 62: 1060-1067, 2002

110. Stratta RJ, Sollinger HW, Perlman SB, D'Alessandro AM, Groshek M, Kalayoglu M, Pirsch JD, Belzer FO: Early diagnosis and treatment of pancreas allograft rejection. Transpl.Int. 1: 6-12, 1988

111. Salazar A, McAlister VC, Kiberd BA, Bitter-Suermann H, Al Kerithy MF, MacDonald AS: Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: effect on renal function. Transplant Proc. 33: 1038-1039, 2001

112. Kaufman DB, Leventhal JR, Stuart J, Abecassis MM, Fryer JP, Stuart FP: Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. Transplantation 67: 586-593, 1999

113. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH: The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 56: 307-315, 1993

114. Matas AJ, Gillingham KJ, Payne WD, Najarian JS: The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 57: 857-859, 1994

115. Matas AJ, Humar A, Payne WD, Gillingham KJ, Dunn DL, Sutherland DE, Najarian JS: Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann.Surg. 230: 493-498, 1999

116. Matas AJ, Humar A, Gillingham KJ, Payne WD, Gruessner RW, Kandaswamy R, Dunn DL, Najarian JS, Sutherland DE: Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int. 62: 704-714, 2002

117. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y, .: The Banff 97 working classification of renal allograft pathology. Kidney Int. 55: 713-723, 1999

118. Drachenberg CB, Papadimitriou JC, Klassen DK, Racusen LC, Hoehn-Saric EW, Weir MR, Kuo PC, Schweitzer EJ, Johnson LB, Bartlett ST: Evaluation of pancreas transplant needle biopsy: reproducibility and revision of histologic grading system. Transplantation 63: 1579-1586, 1997

119. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Fink J, Weir MR, Cangro C, Schweitzer EJ, Bartlett ST: Histologic grading of acute allograft rejection in pancreas needle biopsy: correlation to serum enzymes, glycemia, and response to immunosuppressive treatment. Transplantation 66: 1741-1745, 1998

120. Mueller A, Schnuelle P, Waldherr R, van der Woude FJ: Impact of the Banff '97 classification for histological diagnosis of rejection on clinical outcome and renal function parameters after kidney transplantation. Transplantation 69: 1123-1127, 2000

121. Bates WD, Davies DR, Welsh K, Gray DW, Fuggle SV, Morris PJ: An evaluation of the Banff classification of early renal allograft biopsies and correlation with outcome. Nephrol.Dial.Transplant. 14: 2364-2369, 1999

122. Meehan SM, Siegel CT, Aronson AJ, Bartosh SM, Thistlethwaite JR, Woodle ES, Haas M: The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies. J.Am.Soc.Nephrol. 10: 1806-1814, 1999

123. Macdonald FI, Ashraf S, Picton M, Dyer PA, Parrott NR, Short CD, Roberts IS: Banff criteria as predictors of outcome following acute renal allograft rejection. Nephrol.Dial.Transplant. 14: 1692-1697, 1999

124. Bartlett ST, Schweitzer EJ, Johnson LB, Kuo PC, Papadimitriou JC, Drachenberg CB, Klassen DK, Hoehn-Saric EW, Weir MR, Imbembo AL: Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. Ann.Surg. 224: 440-449, 1996

125. Schulz T, Konzack J, Busing M: Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. Transplant.Proc. 31: 591-592, 1999

126. Reddy KS, Stratta RJ, Shokouh-Amiri H, Alloway R, Somerville T, Egidi MF, Gaber LW, Gaber AO: Simultaneous kidney-pancreas transplantation without antilymphocyte induction. Transplantation 69: 49-54, 2000

127. Stratta RJ: Review of immunosuppressive usage in pancreas transplantation. Clin.Transplant. 13: 1-12, 1999

128. Margreiter R, Klima G, Bosmuller C, Konigsrainer A, Schmid T, Steiner E: Rejection of kidney and pancreas after pancreas-kidney transplantation. Diabetes 38 Suppl 1: 79-81, 1989

129. Hawthorne WJ, Allen RD, Greenberg ML, Grierson JM, Earl MJ, Yung T, Chapman J, Ekberg H, Wilson TG: Simultaneous pancreas and kidney transplant rejection: separate or synchronous events? Transplantation 63: 352-358, 1997

130. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA: Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J.Am.Soc.Nephrol. 12: 368-373, 2001

131. Baan CC, van Riemsdijk-van Overbeeke IC, Balk AH, Vantrimpont PM, Mol WM, Knoop CJ, Niesters HG, Maat LP, Weimar W: Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expression. Clin.Transplant. 15: 276-283, 2001

132. Moore R, Hernandez D, Valantine H: Calcineurin inhibitors and post-transplant hyperlipidaemias. Drug Saf 24: 755-766, 2001

133. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP: Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J.Am.Soc.Nephrol. 13: 221-227, 2002

134. Reddy KS, Johnston TD, Karounas D, Ranjan D: Hospital charges following simultaneous kidney--pancreas transplantation: enteric drainage versus bladder drainage. Clin.Transplant. 14: 375-379, 2000

135. Schulak JA, Henry ML, Munda R, Mayes JT, Bohnengel A: Pancreas transplantation in Ohio: a 15-year outcomes analysis. Surgery 130: 546-552, 2001

136. Sureshkumar KK, Mubin T, Mikhael N, Kashif MA, Nghiem DD, Marcus RJ: Assessment of quality of life after simultaneous pancreas-kidney transplantation. Am.J.Kidney Dis. 39: 1300-1306, 2002

137. Troppmann C, Gruessner AC, Dunn DL, Sutherland DE, Gruessner RW: Surgical complications requiring early relaparotomy after pancreas transplantation: a multivariate risk factor and economic impact analysis of the cyclosporine era. Ann.Surg. 227: 255-268, 1998

138. Pirsch JD, Odorico JS, D'Alessandro AM, Knechtle SJ, Becker BN, Sollinger HW: Posttransplant infection in enteric versus bladder-drained simultaneous pancreas-kidney transplant recipients. Transplantation 66: 1746-1750, 1998

139. Douzdjian V, Abecassis M: Deep wound infections in simultaneous pancreas-kidney transplant recipients on peritoneal dialysis. Nephrol.Dial.Transplant. 10: 533-536, 1995

140. Nakache R, Weinbroum A, Breitman I, Merhav H, Omi-Wasserlauf R, Klausner J: Surgical risk of pancreas transplantation: the influence of pretransplant management with peritoneal dialysis. Transplant.Proc. 33: 2947, 2001

141. Papalois BE, Troppmann C, Gruessner AC, Benedetti E, Sutherland DE, Gruessner RW: Long-term peritoneal dialysis before transplantation and intra-abdominal infection after simultaneous pancreas-kidney transplantations. Arch.Surg. 131: 761-766, 1996

142. Van Biesen W, Vanholder R, Van Loo A, Van D, V, Lameire N: Peritoneal dialysis favorably influences early graft function after renal transplantation compared to hemodialysis. Transplantation 69: 508-514, 2000

143. Perez FM, Rodriguez-Carmona A, Bouza P, Garcia FT, Adeva M, Valdes F, Oliver J: Delayed graft function after renal transplantation in patients undergoing peritoneal dialysis and hemodialysis. Adv.Perit.Dial. 12: 101-104, 1996

144. Joseph JT, Jindal RM: Influence of dialysis on post-transplant events. Clin.Transplant. 16: 18-23, 2002

145. Flechner SM, Modlin CS, Serrano DP, Goldfarb DA, Papajcik D, Mastroianni B, Goormastic M, Novick AC: Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 62: 1235-1241, 1996

146. Humar A, Hassoun A, Kandaswamy R, Payne WD, Sutherland DE, Matas AJ: Immunologic factors: the major risk for decreased long-term renal allograft survival. Transplantation 68: 1842-1846, 1999

147. Hong JC, Kahan BD: Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplantation 71: 1579-1584, 2001

148. Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL: Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol.Cell Biol. 22: 8184-8198, 2002

149. Sehgal SN, Baker H, Vezina C: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J.Antibiot.(Tokyo) 28: 727-732, 1975

150. Vezina C, Kudelski A, Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J.Antibiot.(Tokyo) 28: 721-726, 1975

151. Kahan BD: Sirolimus: a comprehensive review. Expert.Opin Pharmacother. 2: 1903-1917, 2001

152. Kahan BD, Camardo JS: Rapamycin: clinical results and future opportunities. Transplantation 72: 1181-1193, 2001

153. Saunders RN, Metcalfe MS, Nicholson ML: Rapamycin in transplantation: a review of the evidence. Kidney Int. 59: 3-16, 2001

154. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J: Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 68: 1526-1532, 1999

155. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattstrom C, Lebranchu Y, Vialtel P: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-1260, 2000

156. Kahan BD: Potential therapeutic interventions to avoid or treat chronic allograft dysfunction. Transplantation 71: SS52-SS57, 2001

157. Ikonen TS, Gummert JF, Hayase M, Honda Y, Hausen B, Christians U, Berry GJ, Yock PG, Morris RE: Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 70: 969-975, 2000

158. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74: 1070-1076, 2002

159. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72: 777-786, 2001

160. Mahalati K, Kahan BD: A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine a combination therapy. Transplant Proc. 33: 3232-3233, 2001

161. Mital D, Podlasek W, Jensik SC: Sirolimus-based steroid-free maintenance immunosuppression. Transplant Proc. 34: 1709-1710, 2002

162. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N.Engl.J.Med. 343: 230-238, 2000

163. Kahl A, Oppert M, Muller A, Settmacher U, Lepenies J, Klupp J, Kampf D, Neuhaus P, Frei U: Sirolimus in late acute OKT3-resistant and/or steroid-resistant rejection after simultaneous pancreas and kidney transplantation. Transplant.Proc. 34: 2253, 2002

164. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 55: 752-756, 1993

165. Pelletier RP, Cosio F, Henry ML, Bumgardner GL, Davies EA, Elkhammas EA, Ferguson RM: Acute rejection following renal transplantation. Evidence that severity is the best predictor of subsequent graft survival time. Clin.Transplant 12: 543-552, 1998

166. Tesi RJ, Elkhammas EA, Henry ML, Davies EA, Salazar A, Ferguson RM: Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Transplant Proc. 25: 901-902, 1993

167. Humar A, Kerr S, Gillingham KJ, Matas AJ: Features of acute rejection that increase risk for chronic rejection. Transplantation 68: 1200-1203, 1999

168. Frei U, Schindler R, Wieters D, Grouven U, Brunkhorst R, Koch KM: Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction? Nephrol.Dial.Transplant 10: 1206-1211, 1995

169. Joseph JT, Kingsmore DB, Junor BJ, Briggs JD, Mun WY, Jaques BC, Hamilton DN, Jardine AG, Jindal RM: The impact of late acute rejection after cadaveric kidney transplantation. Clin.Transplant 15: 221-227, 2001

170. Burke GW, III, Ciancio G, Figueiro J, Olson L, Gomez C, Rosen A, Suzart K, Miller J: Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen. Transplant Proc. 34: 1918-1919, 2002

171. Kliem V, Radermacher J, Hiss M, Pethig M, Burg M, Brunkhorst R: Conversion to tacrolimus for acute corticosteroid- and antibody- resistant rejection following kidney transplantation. Transplant Proc. 31: 37S-40S, 1999

172. Jordan ML, Naraghi R, Shapiro R, Smith D, Vivas CA, Scantlebury VP, Gritsch HA, McCauley J, Randhawa P, Demetris AJ, McMichael J, Fung JJ, Starzl TE: Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation 63: 223-228, 1997

173. Anonymous: Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Transplantation 61: 722-729, 1996

174. Gruessner RW, Sutherland DE, Drangstveit MB, Troppmann C, Gruessner AC: Use of FK 506 in pancreas transplantation. Transpl.Int. 9 Suppl 1: S251-S257, 1996

175. Casadei DH, del CR, Opelz G, Golberg JC, Argento JA, Greco G, Guardia OE, Haas E, Raimondi EH: A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 71: 53-58, 2001

176. Luke PP, Scantlebury VP, Jordan ML, Vivas CA, Hakala TR, Jain A, Somani A, Fedorek S, Randhawa P, Shapiro R: Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 72: 419-422, 2001

177. Aichberger C, Nussbaumer W, Rosmanith P, Riedmann B, Spechtenhauser B, Feichtinger H, Fend F, Pernthaler H, Ofner D, Schonitzer D, Margreiter R: Plasmapheresis for the treatment of acute vascular rejection in renal transplantation. Transplant Proc. 29: 169-170, 1997

178. Aranda JM, Jr., Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF, Miles M, Hill JA, Sleasman JW, Skoda-Smith S: Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 73: 907-910, 2002

179. Chen H, Wu J, Xu D, Luo H, Daloze P: Rapamycin reverses acute heart, kidney, and pancreas allograft rejection and prevents accelerated heart allograft rejection in the rat. Transplant Proc. 25: 719-720, 1993

180. Slaton JW, Kahan BD: Case report--sirolimus rescue therapy for refractory renal allograft rejection. Transplantation 61: 977-979, 1996

181. Poston RS, Billingham M, Hoyt EG, Pollard J, Shorthouse R, Morris RE, Robbins RC: Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 100: 67-74, 1999

182. Vu MD, Qi S, Xu D, Wu J, Peng J, Daloze P, Sehgal S, Leduc B, Chen H: Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 66: 1575-1580, 1998

183. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, Oppermann S, Kahan BD, Morrisett JD: Effect of sirolimus on the metabolism of apo. Transplantation 72: 1244-1250, 2001

184. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, Opekun AR, Jaffe JS, Oppermann S, Kahan BD: Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J.Lipid Res. 43: 1170-1180, 2002

185. MacDonald AS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71: 271-280, 2001